Ipamorelin dosage: chart, reported range and vial math

How to mix a Ipamorelin vial

These steps are for the 2 mg vial picked in the chart. Change the size there and the amounts here change with it.

1. Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
2. Draw 2 mL of bacteriostatic water into a syringe.
3. Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
4. Swirl the vial gently until the powder is gone. Do not shake it.
5. Write the date and 1 mg/mL on the vial, then put it in the fridge.

What Ipamorelin is

Ipamorelin is a synthetic five amino acid peptide (a growth hormone secretagogue) that makes the pituitary release growth hormone through the GHRP (ghrelin) receptor, not the GHRH receptor. [1]

Other names: ipamorelin acetate, NNC 26-0161.

How it has been given to people: intravenous infusion in every published human dosing study; no published human study of injection under the skin was found.

What to know before reading a dose

• Not an approved medicine in the US or Canada as of the check date. Every dose on record is a trial dose.
• Every human dose on record was given by intravenous infusion in a study or hospital setting, per kilogram of body weight. No published human study of injection under the skin was found.
• The only efficacy trial with published results (postoperative ileus) found no significant benefit over placebo.
• FDA cites a published report of serious adverse events including death with intravenous ipamorelin [10].
• In mice, ipamorelin increased body fat relative to body weight [6]; no human body-composition study was found.
• The claim that ipamorelin does not raise cortisol rests on a swine study in the sources read [1].
• Compounding status is often quoted out of date: as of FDA's pages dated 04/22/2026 and May 14, 2026, ipamorelin acetate is in category 2 only under the 503B policy and is listed as nominated but withdrawn otherwise [10], [11].

Doses on record for Ipamorelin

Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.

What the evidence shows

Each finding is tagged by the kind of study it comes from. Human trials are listed first.

Side effects and warnings

Reported in human studies or on a label:

• In the Phase 2 trial, adverse events of any kind were recorded in 87.5% of the ipamorelin group and 94.8% of the placebo group. All patients had just had bowel surgery. [3]
• The trial authors described 0.03 mg/kg intravenously twice daily for up to 7 days as well tolerated. [3]
• FDA states that a published study identified serious adverse events, including death, when ipamorelin was given intravenously to improve gastric motility. [10]
• FDA says it has no safety information for other injectable routes. [10]
• FDA says compounded ipamorelin may trigger immune reactions by some routes because of possible aggregation or peptide impurities. [10]

Ipamorelin has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.

Storage

Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.

Ipamorelin dosage questions

Sources

Each one was opened on 10 Oct 2026 and matched to the line it supports.

1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PubMed 9849822.
2. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PubMed 10496658.
3. Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PubMed 25331030. Trial NCT00672074.
4. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function clinicaltrials.gov. Trial NCT01280344.
5. Semenistaya E et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal 2015. PubMed 25869809.
6. Lall S et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun 2001. PubMed 11162489.
7. Andersen NB et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res 2001. PubMed 11735244.
8. Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009. PubMed 19289567.
9. Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. PubMed 9879640.
10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks US Food and Drug Administration 2026-04-22. fda.gov.
11. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act US Food and Drug Administration 2026-05-14. fda.gov.
12. Think twice before injecting peptides bought online: unauthorized products can seriously harm you Health Canada 2026-04-09. recalls-rappels.canada.ca.
13. Health Canada Drug Product Database: active ingredient search for ipamorelin (0 records) Health Canada. health-products.canada.ca.
14. The Prohibited List (2026 list as shown on the WADA website) World Anti-Doping Agency. wada-ama.org.

Looked for and not found

• Any human study of ipamorelin injected under the skin. PubMed lists two clinical trial publications for ipamorelin [2], [3], both intravenous; ClinicalTrials.gov lists two ipamorelin trials, both intravenous.
• Human half-life after injection under the skin.
• Results of the second Phase 2 trial, NCT01280344 (320 enrolled, completed May 2014): none posted on ClinicalTrials.gov and no publication linked in the record [4].
• Details of the deaths FDA mentions [10]: they are not described in the abstract of the published Phase 2 trial [3]; the full paper was not read.
• The dose used in the single-volunteer nasal study [5]: not given in the abstract.
• Human confirmation that ipamorelin leaves ACTH and cortisol unchanged: not in the abstracts read. The finding quoted is from swine [1].
• Any human study of ipamorelin combined with CJC-1295.
• ClinicalTrials.gov NCT07717866 mentions ipamorelin only as one of several supplements in an observational veterans study, with no dose; it is not a trial of ipamorelin.
• No approved label anywhere, so no official contraindications, interaction list, missed-dose rule or storage instructions.

Change log

Related

CJC-1295 without DAC dosageCJC-1295 with DAC dosageSermorelin dosageTesamorelin dosageIGF-1 LR3 dosage2 mg vial5 mg vial10 mg vialWhat Ipamorelin isGrowth hormonePeptide dosage chartDosage calculator

DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.